Cosmo Pharmaceuticals N.V. (C43.F)
| Previous Close | 71.00 |
| Open | 72.50 |
| Bid | 72.00 x 11000 |
| Ask | 74.00 x 8000 |
| Day's Range | 71.50 - 72.50 |
| 52 Week Range | 35.00 - 72.50 |
| Volume | |
| Avg. Volume | 34 |
| Market Cap | 1.18B |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | 108.33 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.00 (2.80%) |
| Ex-Dividend Date | May 28, 2024 |
| 1y Target Est | N/A |
- Newsfile
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system ...
- Newsfile
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development program announced. ...
- Newsfile
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
Dublin, Ireland--(Newsfile Corp. - March 19, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN), (NSE: SUNPHARMA) (BSE: 524715) (“Sun Pharma”) has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi® (clascoterone cream 1%). Winlevi® is indicated for the ...
